CAS: 55066-49-4
Mefranal (CAS: 55066-49-4) is a chemical compound classified as a quinazolinone derivative. It exhibits anxiolytic, sedative, and hypnotic properties. Its mechanism of action is believed to involve modulation of the GABAergic system in the central nervous system, similar to benzodiazepines, leading to a depressant effect on the brain. It was developed and studied for its potential as a tranquilizer.
Mefranal was investigated for its potential therapeutic use as an anxiolytic agent for the treatment of anxiety disorders and as a sedative-hypnotic for insomnia. Its primary intended use was to alleviate symptoms of anxiety and promote sleep.
In a research context, Mefranal has been applied in pharmacological studies to understand its effects on the central nervous system, particularly its interaction with GABA receptors. Therapeutically, it was envisioned for oral administration as a pharmaceutical drug, though it does not appear to have reached widespread clinical approval or market availability.
Like other CNS depressants, Mefranal's safety profile would likely include side effects such as drowsiness, sedation, dizziness, and impaired motor coordination. There is a potential for tolerance, dependence, and withdrawal symptoms, although less extensively documented than for more common benzodiazepines. Overdose could lead to severe CNS depression. Due to its limited clinical use, comprehensive human safety data may be less available compared to approved medications.
3-Methyl-2-phenyl-4(3H)-quinazolinoneRo 7-00433-methyl-2-phenyl-1H-quinazolin-4-oneQuinazolinone3-methyl-2-phenyl-UNII-M58W33R30N
Search suppliers instantly using CAS or chemical name
Search Suppliers →